The Latest Analyst Ratings for Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Sarepta Therapeutics (NASDAQ:SRPT) has received various analyst ratings over the last quarter, with 4 bullish, 6 somewhat bullish, and 2 indifferent ratings. The average 12-month price target for SRPT is $123.83, which is a 22.42% decrease from the previous target of $159.62. The ratings suggest a generally positive outlook from analysts, despite the lowered price target.
December 12, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics has a majority of positive ratings from analysts and a new average price target of $123.83, indicating a positive but cautious short-term outlook.
The predominance of bullish and somewhat bullish ratings suggests that analysts see potential in Sarepta Therapeutics, which could lead to investor optimism and a potential increase in the stock price. However, the decrease in the average price target may temper expectations, indicating a more cautious outlook that could moderate the stock's short-term growth.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100